Pharmaron Beijing Co., Ltd. Share Price
Equities
300759
CNE100003JW4
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.21 CNY | +0.62% |
|
+0.90% | +13.66% |
| Capitalization | 48.92B 6.92B 5.95B 5.57B 5.19B 9.59B 623B 10.43B 65.18B 25.17B 294B 25.97B 25.42B 1,075B | P/E ratio 2025 * |
29.6x | P/E ratio 2026 * | 24.2x |
|---|---|---|---|---|---|
| Enterprise value | 52.54B 7.43B 6.39B 5.98B 5.58B 10.3B 669B 11.21B 70B 27.03B 316B 27.89B 27.3B 1,155B | EV / Sales 2025 * |
3.73x | EV / Sales 2026 * | 3.2x |
| Free-Float |
48.56% | Yield 2025 * |
0.71% | Yield 2026 * | 0.87% |
| 1 day | +0.62% | ||
| 1 week | +0.90% | ||
| Current month | +0.90% | ||
| 1 month | -7.77% | ||
| 3 months | -6.68% | ||
| 6 months | +22.73% | ||
| Current year | +13.66% |
| 1 week | 28.57 |  | 29.68 |
| 1 month | 28.11 | | 32.1 |
| Current year | 20.47 | | 37.63 |
| 1 year | 20.47 | | 37.63 |
| 3 years | 17.7 | | 56.91 |
| 5 years | 17.7 | | 108.71 |
| 10 years | 4.08 | | 108.71 |
| Manager | Title | Age | Since |
|---|---|---|---|
Xiao Qiang Lou
PSD | President | 56 | - |
Bei Zheng
PRN | Corporate Officer/Principal | 58 | 26/10/2016 |
Bo Liang Lou
CEO | Chief Executive Officer | 61 | 26/10/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Bo Liang Lou
CHM | Chairman | 61 | 26/10/2016 |
Bei Zheng
BRD | Director/Board Member | 58 | 26/10/2016 |
Ke Xin Yang
CHM | Chairman | 63 | 26/10/2016 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 1.17% | 0 M€ | -19.71% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.62% | +0.90% | -1.15% | -33.83% | 6.92B | |
| +0.77% | -1.12% | +5.82% | +20.13% | 47.37B | |
| +0.41% | -1.81% | +11.46% | +8.74% | 38.46B | |
| -2.56% | -5.20% | +57.04% | +66.98% | 35.73B | |
| +0.38% | -1.24% | +11.14% | +19.30% | 27.23B | |
| +0.61% | -7.48% | +56.37% | +165.22% | 15.44B | |
| +1.48% | +2.42% | +65.68% | +229.77% | 15.4B | |
| +0.05% | +0.47% | -14.53% | -5.60% | 14.19B | |
| +0.43% | -1.63% | +51.98% | - | 13.64B | |
| -0.16% | -1.27% | +114.33% | +113.82% | 13.23B | |
| Average | +0.20% | -1.86% | +35.81% | +64.95% | 22.76B | |
| Weighted average by Cap. | +0.05% | -2.07% | +30.52% | +53.69% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 14.08B 1.99B 1.71B 1.6B 1.49B 2.76B 179B 3B 18.75B 7.24B 84.62B 7.47B 7.31B 309B | 16.06B 2.27B 1.95B 1.83B 1.7B 3.15B 204B 3.42B 21.39B 8.26B 96.53B 8.52B 8.34B 353B |
| Net income | 1.72B 243M 209M 196M 183M 338M 21.91B 367M 2.29B 885M 10.35B 914M 894M 37.84B | 2.18B 308M 265M 248M 231M 427M 27.72B 465M 2.9B 1.12B 13.09B 1.16B 1.13B 47.88B |
| Net Debt | 3.62B 512M 440M 412M 384M 710M 46.07B 772M 4.82B 1.86B 21.76B 1.92B 1.88B 79.56B | 2.5B 354M 304M 285M 266M 491M 31.85B 534M 3.33B 1.29B 15.04B 1.33B 1.3B 54.99B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 29.21 ¥ | +0.62% | 10,689,830 |
| 04/12/25 | 29.03 ¥ | +0.66% | 14,241,880 |
| 03/12/25 | 28.84 ¥ | -0.55% | 8,611,705 |
| 02/12/25 | 29.00 ¥ | -2.23% | 11,303,570 |
| 01/12/25 | 29.66 ¥ | +2.45% | 18,992,640 |
End-of-day quote Shenzhen S.E., December 04, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300759 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition